NeuraLight Eye Exam for Parkinson's Disease (PALOMA Trial)

"Patients aged 40 to 85 are the only ones that meet this trial's inclusion criteria. There are 23 trials for those under 18 while 529 studies target individuals older than 65 years of age."

"At present, this research venture is being conducted at 5 different sites. These include Coimbra, Sevilla and Zürich in addition to other municipalities. To minimize the burden of travel for potential participants, it would be beneficial to select a location that is geographically close by."

"Affirmative. According to the details posted on clinicaltrials.gov, this experiment is currently recruiting participants. It was first announced on August 21st 2023 and last amended October 3rd 2023. The trial requires 300 recruits from 5 various medical facilities."

"Affirmative, clinicaltrials.gov data points to this trial presently seeking volunteers; the study first appeared on August 21st 2023 and was recently edited October 3rd 2023. This medical investigation is looking for 300 participants from 5 distinct sites."

"This research project recruiting 300 patients with Parkinson's disease aged between 40 and 85. To be eligible, participants must have received their diagnosis no more than 5 years ago, display mild to moderate symptoms (Hoehn & Yahr scale 1-2), possess normal or corrected vision, understand the study information provided in order to give informed consent, remain stable on PD medications for 3 months prior to enrollment if they are already taking them."

"As per NeuraLight, the primary outcome being measured over 12 months is the link between MDS-UPDRS score and saccadic latency. Additionally, secondary outcomes include a correlation between Montreal Cognitive Assessment (MoCA) with smooth pursuit speed as well as optimisation of feature selection model for logistic regression modelling of MoCA via collected oculometric measures relative root mean square error below 0.1, and finally correlation between MoCA score and its parts with saccadic latency."